Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 3Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 78Melanoma 51Squamous Cell Carcinoma of Head and Neck 40Neoplasm Metastasis 30Neoplasms 27Breast Neoplasms 26Colorectal Neoplasms 23Carcinoma, Renal Cell 23Head and Neck Neoplasms 21Triple Negative Breast Neoplasms 20Carcinoma, Transitional Cell 20Stomach Neoplasms 19Ovarian Neoplasms 17Lung Neoplasms 15Uterine Cervical Neoplasms 12Esophageal Neoplasms 12Carcinoma, Hepatocellular 12Urinary Bladder Neoplasms 11Parkinson Disease 4, Autosomal Dominant Lewy Body 11Pancreatic Neoplasms 10Small Cell Lung Carcinoma 9Multiple Myeloma 9Recurrence 8Endometrial Neoplasms 8Carcinoma, Merkel Cell 8Lymphoma, Non-Hodgkin 7Lymphoma 7Skin Neoplasms 6Mesothelioma 6Hodgkin Disease 6

Interventions

Lenalidomide 5Rituximab 4Brentuximab Vedotin 4Vincristine 3Etoposide 3Cyclophosphamide 3romidepsin 2Vorinostat 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Doxorubicin 2Dasatinib 2tislelizumab 1selinexor 1plerixafor 1pembrolizumab 1pegfilgrastim 1parsaclisib 1obinutuzumab 1obatoclax 1monomethyl auristatin E 1liposomal doxorubicin 1ixazomib 1idelalisib 1ibrutinib 1gemcitabine-oxaliplatin regimen 1fludarabine 1etoposide phosphate 1denileukin diftitox 1copanlisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma, T-Cell, Peripheral × pembrolizumab × Clear all
NCT02535247 2022-07-08

Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma

Fox Chase Cancer Center

Phase 1/2 Terminated
17 enrolled 7 charts
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡